Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from BRUIN

被引：0

作者：

Munir, Talha ^{[1
]}

Mato, Anthony R. ^{[2
]}

Woyach, Jennifer A. ^{[3
]}

Brown, Jennifer R. ^{[4
,5
]}

Ghia, Paolo ^{[6
,7
]}

Patel, Krish ^{[8
]}

Eyre, Toby A. ^{[9
]}

Lech-Maranda, Ewa ^{[10
]}

Lamanna, Nicole ^{[11
]}

Tam, Constantine S. ^{[12
,13
]}

Seymour, John F. ^{[12
,13
]}

Shah, Nirav N. ^{[14
]}

Coombs, Catherine C. ^{[15
]}

Ujjani, Chaitra S. ^{[16
]}

Patel, Manish R. ^{[17
]}

Fakhri, Bita ^{[18
]}

Cheah, Chan Y. ^{[19
,20
]}

Alencar, Alvaro J. ^{[21
]}

Cohen, Jonathon B. ^{[22
]}

Gerson, James N. ^{[23
]}

Flinn, Ian W. ^{[24
]}

Ma, Shuo ^{[25
]}

Jagadeesh, Deepa ^{[26
]}

Rhodes, Joanna M. ^{[27
]}

Hernandez-Ilizaliturri, Francisco ^{[28
]}

Zinzani, Pier Luigi ^{[29
]}

Balbas, Minna ^{[30
]}

Nair, Binoj ^{[30
]}

Abada, Paolo ^{[30
]}

Wang, Chunxiao ^{[31
]}

Wang, Denise ^{[30
]}

Tsai, Donald E. ^{[30
]}

Wierda, William G. ^{[32
]}

Jurczak, Wojciech ^{[33
]}

机构：

[1] St James Hosp, Leeds, W Yorkshire, England

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[4] Dana Farber Canc Inst, Boston, MA USA

[5] Harvard Med Sch, Boston, MA USA

[6] Univ Vita Salute San Raffaele, Milan, Italy

[7] IRCCS Osped San Raffaele, Milan, Italy

[8] Swedish Canc Inst, Ctr Blood Disorders & Cellular Therapy, Seattle, WA USA

[9] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[10] Inst Hematol & Transfus Med, Warsaw, Poland

[11] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[12] Peter MacCallum Canc Ctr, Melbourne, Australia

[13] Univ Melbourne, Melbourne, Australia

[14] Med Coll Wisconsin, Milwaukee, WI USA

[15] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[16] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[17] Florida Canc Specialists Sarah Cannon Res Inst, Sarasota, FL USA

[18] Univ Calif San Francisco, San Francisco, CA USA

[19] Linear Clin Res, Perth, Australia

[20] Sir Charles Gairdner Hosp, Perth, Australia

[21] Univ Miami, Miller Sch Med, Miami, FL USA

[22] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[23] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[24] Sarah Cannon Res Inst, Nashville, TN USA

[25] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL USA

[26] Cleveland Clin, Cleveland, OH USA

[27] Northwell Hlth, Northwell Hlth Canc Inst, Donald & Barbara Zucker Sch Med Hofstra, New Hyde Pk, NY USA

[28] Roswell Pk Comprehens Canc Ctr, Lymphoma Sect, Dept Med Oncol, Buffalo, NY USA

[29] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[30] Loxo Lilly, Indianapolis, IN USA

[31] Eli Lilly & Co, Indianapolis, IN USA

[32] MD Anderson Canc Ctr, Houston, TX USA

[33] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-PO84

引用

页码：110 / 111

页数：2

共 50 条

[11] Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Coombs, Catherine C.
Pagel, John M.
Shah, Nirav N.
Lamanna, Nicole
Munir, Talha
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Y.
Cohen, Jonathon B.
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David
Gerson, James N.
Alencar, Alvaro
Ujjani, Chaitra
Flinn, Ian
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald E.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S268 - S269
[12] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
Mato, Anthony
Pagel, John
Coombs, Catherine
Shah, Nirav
Lamanna, Nicole
Munir, Talha
Lech-Maranda, Ewa
Eyre, Toby
Woyach, Jennifer
Wierda, William
Cheah, Chan
Cohen, Johnathan
Roeker, Lindsey
Patel, Manish
Fakhri, Bita
Barve, Minal
Tam, Constantine
Lewis, David
Gerson, James
Alencar, Alvaro
Ujjani, Chaitra
Flinn, Ian
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald
Davids, Matthew
Brown, Jennifer
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 97 - 101
[13] Efficacy of Pirtobrutinib in Relapsed/ Refractory CLL and Richter Transformation: Additional Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 16 - 16
[14] Pirtobrutinib; A Next Generation; Highly Selective; Non-covalent BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Weirda, William G.
Cheah, Chan Y.
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine
Lewis, David
Gerson, James N.
Alencar, Alvaro J.
Ghia, Paolo
Schuster, Stephen J.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 168 - 169
[15] Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results fro the Phase 1/2 BRUIN Study
Mato, Anthony R.
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Munir, Tahla
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Yoon
Cohen, Jonathon B.
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David John
Gerson, James N.
Alencar, Alvaro J.
Ujjani, Chaitra S.
Flinn, Ian W.
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
BLOOD, 2021, 138
[16] Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenstrom Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
Palomba, M. Lia
Patel, Manish R.
Eyre, Toby A.
Jurczak, Wojciech
Lewis, David John
Gastinne, Thomas
Ma, Shuo
Cohen, Jonathon B.
Patel, Krish
Brown, Jennifer R.
Scarfo, Lydia
Munir, Talha
Lech-Maranda, Ewa
Hoffmann, Marc
Ujjani, Chaitra S.
Fakhri, Bita
Wang, Michael L.
Izutsu, Koji
Nagai, Hirokazu
Tam, Constantine S.
Seymour, John F.
Rhodes, Joanna M.
Vose, Julie M.
McKinney, Matthew
Gerson, James N.
Barve, Minal A.
Kuss, Bryone J.
Koh, Youngil
Gao, Wei
Ruppert, Amy S.
Walgren, Richard A.
Tsai, Donald E.
Nair, Binoj
Bao, Katherine
Mato, Anthony R.
Cheah, Chan Y.
BLOOD, 2022, 140
[17] Matching-adjusted indirect comparison of pirtobrutinib vs. venetoclax continuous monotherapy in patients with relapsed/refractory CLL previously treated with a covalent BTK inhibitor
Davids, Matthew
Al-Sawaf, Othman
Jen, Min-Hua
Hess, Lisa M.
Zhang, Jiewen
Goebel, Benjamin
Pagel, John M.
Eyre, Toby A.
LEUKEMIA & LYMPHOMA, 2023, 64 : S78 - S79
[18] Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Coombs, Catherine C.
Pagel, John M.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Y.
Roeker, Lindsey
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David J.
Gerson, James N.
Alencar, Alvaro
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S315 - S316
[19] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study
Shah, Nirav N.
Zinzani, Pier Luigi
Wang, Michael L.
Nasta, Sunita D.
Lech-Maranda, Ewa
Ogawa, Yoshiaki
Fakhri, Bita
Kuss, Bryone
Miyashita, Kaname
Patel, Krish
Coombs, Catherine C.
Ma, Shuo
Patel, Manish
Barve, Minal A.
Tessoulin, Benoit
Stathis, Anastasios
Kim, Won Seog
Ennishi, Daisuke
Hashimoto, Daigo
Kojima, Kensuke
Zelenetz, Andrew D.
Cohen, Jonathon B.
Vose, Julie M.
Maddocks, Kami J.
Munir, Talha
Sun, Fangfang
Bian, Faith
Tsai, Donald E.
Abada, Paolo
Cheah, Chan Y.
BLOOD, 2023, 142
[20] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study
Patel, Krish
Vose, Julie M.
Nasta, Sunita D.
Brown, Jennifer R.
Maddocks, Kami J.
Woyach, Jennifer A.
Shah, Nirav N.
Fakhri, Bita
Tessoulin, Benoit
Ma, Shuo
Jagadeesh, Deepa
Lech-Maranda, Ewa
Coombs, Catherine C.
Patel, Manish
Rhodes, Joanna M.
Ujjani, Chaitra S.
Hoffmann, Marc S.
Cheah, Chan Y.
Munir, Talha
Lewis, David
Scarfo, Lydia
Eyre, Toby A.
Alencar, Alvaro J.
Cohen, Jonathon B.
Zelenetz, Andrew D.
Tsai, Donald E.
Li, Mei
Bian, Faith
Abada, Paolo
Zinzani, Pier Luigi
BLOOD, 2023, 142

← 1 2 3 4 5 →